AAPG — ASCENTAGE PHARMA GROUP INTERNATIONAL
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023311 ·
China
Last close
$13.14
Market Cap
$1.23B
52W High
$33.09
52W Low
$13.12
ADV30
7,648
Next earnings
2026-08-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 3,240,702,000 | 1,895,583,000 | 2,674,869,000 |
| Dec 2025 | — | — | — | — | 3,963,577,000 | 2,464,400,000 | 2,629,365,000 |
| Jun 2025 | — | — | — | — | 3,046,144,000 | 1,661,454,000 | 2,370,235,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,830,018,000
Inventory
$64,300,000
Receivables
$333,381,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$642,635,008
EBITDA
$-1,335,864,064
Free Cash Flow
$-956,540,352
Enterprise Value
$1,710,758,016
Total Cash
$1,895,582,976
Total Debt
$2,094,571,008
Shares Out
93,388,942
Trailing EPS
$-2.35
Book Value
$0.89
ROE
-236.6%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 574,120,000 | -1,197,691,000 | -1,242,769,000 | 3,963,577,000 | 2,629,365,000 | 1,324,462,000 | -1,174,128,000 |
| Dec 2024 | 980,650,000 | -369,730,000 | -405,433,000 | 2,617,810,000 | 2,343,648,000 | 264,194,000 | -111,357,000 |
| Dec 2023 | 221,984,000 | -872,636,000 | -925,637,000 | 2,500,393,000 | 2,429,761,000 | 60,417,000 | -726,077,000 |
| Dec 2022 | 209,711,000 | -849,810,000 | -882,924,000 | 2,830,261,000 | 2,421,603,000 | 408,658,000 | -653,915,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTR | NEKTAR THERAPEUTICS | $1.23B | $35.91 | — |
| SLN | Silence Therapeutics plc | $1.23B | $19.80 | — |
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| SLNCF | Silence Therapeutics plc | $1.22B | $6.53 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
News headlines (Yahoo Finance, 1h cache)
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
2026-11-15 23:30 · Yahoo
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
2026-11-04 23:30 · Yahoo
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
2026-11-03 12:30 · Yahoo
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
2026-10-20 23:30 · Yahoo
Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall
2026-10-19 19:14 · Yahoo
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
2026-10-10 14:35 · Yahoo
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
2026-10-05 14:55 · Yahoo
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary
2026-08-21 12:30 · Yahoo
Ascentage Pharma Group International H1 Earnings Call Highlights
2026-08-20 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.